| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 200 mg | 300 mg | 2 mL | 26 weeks | 87 |
| Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial 2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years | 2.2 g | 1.1 g | — | — | 33 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 71.9 mg/kg | 242 mg/kg | 10 mL | 1 year | 33 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 600 mg | 900 mg | 5 g | 90 days | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 780 mg | 2.13 g | 1.35 g | 12 weeks | 27 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 780 mg | 940 mg | 2 g | 30 days | 18 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 800 mg | 1.6 g | 2.4 g | 24 weeks | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 120 mg | 300 mg | 1 g | 90 days | 15 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 260 mg | 600 mg | 2.4 g | 62 days | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 1 g | 2 g | 5 g | 12 weeks | 12 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 260 mg | 600 mg | 2.4 g | 62 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 1.58 g | 2.28 g | 4.5 g | 10 weeks | 10 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 260 mg | 600 mg | 2.4 g | 62 days | 8 |
| Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes 2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported | 2.2 g | — | 3.2 g | 3 weeks | 5 |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 400 mg | 300 mg | 2 g | 8 weeks | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.14 g | 1.71 g | 1.71 g | 1 year | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 400 mg | 1 g | 2 g | 18 weeks | 134 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 480 mg | 1.42 g | 2 g | 12 weeks | 40 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 400 mg | 600 mg | 2 g | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 2.6 g | 20 mL | 26 weeks | 24 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 137 mg | 590 mg | — | 30 days | 22 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 417 mg | 159 mg | — | 30 days | 22 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 2.6 g | 20 mL | 90 days | 20 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 504 mg | 120 mg | 2 g | 6 weeks | 16 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 140 mg | 216 mg | 216 mg | 6 weeks | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 225 mg | 706 mg | 706 mg | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 1.95 g | 3 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 1.95 g | 3 g | 16 weeks | — |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 1.2 g | 1.6 g | 4 g | 12 weeks | 12 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 3.7 g | 1.7 g | 9.6 g | 4 weeks | 21 |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · ethyl ester (EE) · healthy normolipaemic men | 1.2 g | 2.2 g | — | 7 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · triglyceride (TG) · healthy normolipaemic men | 1.4 g | 2.2 g | — | 7 weeks | — |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.5 g | 1.86 g | 3.36 g | 1 year | 147 |
| Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial 2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery | 1 g | 2 g | — | 7 days | 74 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 1.8 g | 4.4 g | 4.4 g | 30 days | 40 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 1.45 g | 2.15 g | 2.15 g | 6 weeks | 21 |
| Dietary supplementation with fish oil in ulcerative colitis 1992 · fish oil · Adults with active ulcerative colitis | 2.16 g | 3.24 g | — | 120 days | 18 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 900 mg | 700 mg | 8 g | 7 weeks | 17 |
| Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes 2000 · Fish oil · Postmenopausal women | 1.4 g | 2 g | — | — | 15 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · High DHA-FO concentrate · Obese men and women with BMI >30 | 2 g | 400 mg | — | 12 weeks | 12 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 4.4 g | 4.4 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 4.4 g | 4.4 g | 90 days | 11 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 1 g | 1.4 g | 4 g | 12 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 1.1 g | 2.1 g | 9 g | 12 weeks | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 800 mg | 1.1 g | 3 g | 12 weeks | — |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 1.2 g | 3.6 g | 6 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 200 mg | 1.05 g | 1.05 g | — | 10 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 120 mg | 180 mg | 180 mg | 4 weeks | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 225 mg | 800 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 225 mg | 800 mg | 3 years | 399 |